ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

ASPCF Acerus Pharmaceuticals Corporation (QB)

0.21988
0.00 (0.00%)
Mar 27 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0.00
Bid Price
Ask Price
News -
Company Name Stock Ticker Symbol Market Type
Acerus Pharmaceuticals Corporation (QB) ASPCF OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 0.21988 20:00:00
Open Price Low Price High Price Close Price Prev Close
0.21988
Trades Volume Avg Volume
0 0.00 -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.21988 USD

Acerus Pharmaceuticals Corporation (QB) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.69M 7.71M 662.94k - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Acerus Pharmaceuticals (QB) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ASPCF Message Board. Create One! See More Posts on ASPCF Message Board See More Message Board Posts

Historical ASPCF Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Acerus Pharmaceuticals (QB) Description

Acerus is a Canadian pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve the patient experience. Founded in 2008, Acerus has quickly grown into a fully integrated company with expertise in all stages of the pharmaceutical product lifecycle, and focus in the therapeutic areas of Men's Health (Urology) and Women's Health (Hormone Replacement Therapy). Acerus has global rights to NATESTO, a product utilizing our licensed nasal gel technology, is the first and only testosterone nasal gel approved in Canada, and the United States for replacement therapy in adult males diagnosed with hypogonadism. Acerus operates from a Mississauga-based office, and is listed on the Toronto Stock Exchange (TSX:ASP)

Your Recent History

Delayed Upgrade Clock